What is the clinical evidence from this study?

Study design: Review. Population: Heart failure in kidney transplant recipients.

What question did this study set out to answer?

To review traditional and nontraditional risk factors for heart failure among kidney transplant recipients, assess barriers to guideline-directed medical therapy, and outline strategies to improve clinical management.

February 26, 2026Cardiology and TherapyOpen Access

Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management

View Full Paper

Ask AI

Bookmark

Key result

GDMT uptake remains low in kidney transplant recipients with HF, as RASi use falls below ~27%.

Why the study?

Kidney transplant recipients have a high burden of heart failure but have been excluded from major cardiovascular trials, leading to uncertainty regarding guideline-directed medical therapy safety and efficacy.

Design

Narrative review

Authors

AGAnukul GhimireUniversity Health Network GAGaeth Al-ZaneenDalhousie University JMJacob B. MichaudDalhousie University

Discussion

Member takes

Implication

Warrants caution in applying standard GDMT to kidney transplant recipients with HF; leaves open safety, efficacy, and kidney protection pending dedicated trials.

Key Points

To review traditional and nontraditional risk factors for heart failure among kidney transplant recipients, assess barriers to guideline-directed medical therapy, and outline strategies to improve clinical management.
Narrative review searching PubMed from inception to December 2025 using terms 'heart failure', 'kidney transplant', and 'kidney failure'.
Synthesized observational and clinical evidence on heart failure epidemiology, phenotypes, and guideline-directed drug classes in kidney transplant recipients.
Heart failure remains common post-transplantation, with previous work reporting an 18% incidence of de novo heart failure within 12 months after transplant.
Kidney transplant recipients have systematically been excluded from major cardiovascular clinical trials and landmark studies evaluating novel cardiorenal agents such as sodium-glucose cotransporter 2 inhibitors.
Uptake of guideline-directed medical therapy is hindered by clinical risks of hyperkalemia from renin-angiotensin-aldosterone blockade, fears of genitourinary infections from SGLT2 inhibitors, and absent dedicated trial safety data.

Structured PICO

Population

Kidney transplant recipients (KTR) with or at risk for heart failure and cardiovascular disease

Intervention

Guideline-directed medical therapy (GDMT) for heart failure, including renin-angiotensin system inhibitors (RASi), beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2i)

There is a critical evidence gap regarding the safety and efficacy of guideline-directed medical therapy for heart failure in kidney transplant recipients, highlighting the need for dedicated trials and multidisciplinary care strategies.

Limitations

Lack of randomized controlled trials specifically including kidney transplant recipients with heart failure.
Most data are from observational studies or indirect evidence from non-transplant populations.
Many studies have small sample sizes or focus on kidney outcomes rather than heart failure.
Limited data on long-term outcomes and safety of GDMT in kidney transplant recipients.
Potential for publication bias and heterogeneity in included studies.
Narrative review without a formal search strategy or specific inclusion/exclusion criteria
Lack of dedicated interventional trials in kidney transplant recipients to assess cardiovascular outcomes

Cite This Study

Ghimire et al. (2026) conducted a review in Heart failure in kidney transplant recipients. This narrative review found that guideline directed medical therapy (GDMT) uptake in kidney transplant recipients with heart failure is low, with beta-blocker use ranging from 64% to 76% at 1 to 2 years post-transplant, while renin–angiotensin system inhibitor use falls to 16%-27%, and mineralocorticoid receptor antagonist and SGLT2 inhibitor use is minimal or absent.

synapsesocial.com/papers/699fe28895ddcd3a253e64ca https://doi.org/10.1007/s40119-026-00446-8

Topics

Heart failure HFrEF treatment SGLT2 inhibitors in heart failure HFpEF management

View Full Paper

Ask AI

Bookmark

Implication

Warrants caution in applying standard GDMT to kidney transplant recipients with HF; leaves open safety, efficacy, and kidney protection pending dedicated trials.

Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider